Is there really a power shortage in clinical trials testing the "homocysteine hypothesis?".
G J
GJ
Hankey
J W
JW
Eikelboom
K
K
Loh
Q
Q
Yi
J
J
Pizzi
M
M
Tang
S
S
Hickling
M
M
Le
C J M
CJ
Klijn
P
P
Dusitanond
F
F
van Bockxmeer
A
A
Gelavis
R
R
Baker
K
K
Jamrozik
D001315:Australia / Q000453:epidemiology; D015331:Cohort Studies; D004311:Double-Blind Method; D002523:Edible Grain; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005527:Food, Fortified; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D002546:Ischemic Attack, Transient / Q000209:etiology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D018401:Sample Size; D055502:Secondary Prevention; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D019851:Thrombophilia / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014805:Vitamin B 12 / Q000008:administration & dosage / Q000627:therapeutic use*; D025101:Vitamin B 6 / Q000008:administration & dosage / Q000627:therapeutic use*
D025101:Vitamin B 6; D005492:Folic Acid; D014805:Vitamin B 12